Trial Profile
A study to investigate OCB-030
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 07 Aug 2015
Price :
$35
*
At a glance
- Drugs OCB 030 (Primary)
- Indications Hepatitis B; Hepatitis C
- Focus Adverse reactions
- 07 Aug 2015 New trial record
- 05 Aug 2015 According to an Arbutus Biopharma media release, the company expects to file an IND for OCB-030 in the fourth quarter of 2015.